A series of eighteen novel esters of salicylanilides with benzenesulfonic acid were designed, synthesized and characterized by IR, ¹H-NMR and ¹³C-NMR. They were evaluated in vitro as potential antimycobacterial agents towards Mycobacterium tuberculosis, Mycobacterium avium and two strains of Mycobacterium kansasii. In general, the minimum inhibitory concentrations range from 1 to 500 µmol/L. The most active compound against M. tuberculosis was 4-chloro-2-(4-(trifluoromethyl)phenylcarbamoyl)-phenyl benzenesulfonate, with MIC of 1 µmol/L and towards M. kansasii its isomer 5-chloro-2-(4-(trifluoromethyl)phenylcarbamoyl)phenyl benzenesulfonate (MIC of 2-4 µmol/L). M. avium was the less susceptible strain. However, generally, salicylanilide benzenesulfonates did not surpass the activity of other salicylanilide esters with carboxylic acids.

Department of Inorganic and Organic Chemistry Faculty of Pharmacy Charles University Heyrovského 1203 50005 Hradec Králové Czech Republic

See more in PubMed

WHO. 2011/2012 Tuberculosis Global Facts. [(accessed on 28 October 2011)]. Available online: http://www.who.int/tb/publications/2011/factsheet_tb_2011.pdf.

Vinsova J., Kratky M. Development of New MDR-Tuberculosis Drugs. 1st. Nova Science Publishers; New York, NY, USA: 2010.

Kratky M., Vinsova J. Advances in the Development of Antituberculotics Acting on Multidrug-Resistant Strains. Chem. Listy. 2010;104:998–1005.

Sugita A., Ogawa H., Azuma M., Muto S., Honjo A., Yanagawa H., Nishioka Y., Tani K., Itai A., Sone S. Antiallergic and anti-inflammatory effects of a novel IkB kinase b inhibitor, IMD-0354, in a mouse model of allergic inflammatio. Int. Arch. Allergy Immunol. 2009;148:186–198. doi: 10.1159/000161579. PubMed DOI

Brown M.E., Fitzner J.N., Stevens T., Chin W., Wright C.D., Boyce J.P. Salicylanilides: Selective inhibitors of interleukin-12p40 production. Bioorg.Med. Chem. 2008;16:8760–8764. doi: 10.1016/j.bmc.2008.07.024. PubMed DOI

Zhong G.X., Chen L.L., Li J., Hu W.X., Qi M.Y. Synthesis and anti-inflammatory-analgesic activity of 2′,4′-difluoro-3-(carbamoyl)biphenyl-4-yl benzoates. Chin. Chem. Lett. 2008;19:1419–1422. doi: 10.1016/j.cclet.2008.09.018. DOI

Calderone V., Coi A., Fiamingo F.L., Giorgi I., Leonardi M., Livi O., Martelli A., Martinotti E. Structural modifications of benzanilide derivatives, effective potassium channel openers. X. Eur. J. Med. Chem. 2006;41:1421–1429. doi: 10.1016/j.ejmech.2006.07.016. PubMed DOI

Liechti C., Séquin U., Bold G., Furet P., Meyer T., Traxler P. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. Eur. J. Med. Chem. 2004;39:11–26. doi: 10.1016/j.ejmech.2003.09.010. PubMed DOI

Zhu X.F., Wang J.S., Cai L.L., Zeng Y.X., Yang D. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells. Cancer Sci. 2006;97:84–89. doi: 10.1111/j.1349-7006.2006.00143.x. PubMed DOI PMC

Krátký M., Vinšová J. Antiviral Activity of Substituted Salicylanilides—A Review. Mini-Rev. Med. Chem. 2011;97:956–967. PubMed

Krátký M., Vinšová J. Salicylanilide Ester Prodrugs as Potential Antimicrobial Agents—A Review. Curr. Pharm. Des. 2011;17:3494–3505. doi: 10.2174/138161211798194521. PubMed DOI

Hamilton W.A. Mechanism of the Bacteriostatic Action of Tetrachlorosalicylanilide—A Membrane Active Antibacterial Compound. J. Gen. Microbiol. 1968;50:441–458. doi: 10.1099/00221287-50-3-441. PubMed DOI

Terada H., Goto S., Yamamoto K., Takeuchi I., Hamada Y., Miyake K. Structural requirements of salicylanilides for uncoupling activity in mitochondria: Quantitative analysis of structure-uncoupling relationships. Biochim.Biophys. Acta. 1988;936:504–512. doi: 10.1016/0005-2728(88)90027-8. PubMed DOI

Macielag M.J., Demers J.P., Fraga-Spano S.A., Hlasta D.J., Johnson S.G., Kanojia R.M., Russel R.K., Sui Z.H., Weidner-Wells M.A., Werblood H., et al. Substituted Salicylanilides as Inhibitors of Two-Component Regulatory Systems in Bacteria. J. Med. Chem. 1998;41:2939–2945. doi: 10.1021/jm9803572. PubMed DOI

Krátký M., Vinšová J., Buchta V., Horvati K., Bösze S., Stolaříková J. New amino acid esters of salicylanilides active against MDR-TB and other microbes. Eur. J. Med. Chem. 2010;45:6106–6113. doi: 10.1016/j.ejmech.2010.09.040. PubMed DOI

Glowienke S., Frieauff W., Allmendinger T., Martus H.J., Suter W., Mueller L. Structure–activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters. Mutat.Res. 2005;581:23–34. doi: 10.1016/j.mrgentox.2004.10.004. PubMed DOI

Imramovský A., Vinšová J., Férriz J.M., Doležal R., Jampílek J., Kaustová J., Kunc F. New antituberculotics originated from salicylanilides with promising in vitro activity against atypical mycobacterial strains. Bioorg.Med. Chem. 2009;17:3572–3579. doi: 10.1016/j.bmc.2009.04.008. PubMed DOI

Vinsova J., Imramovsky A., Buchta V., Ceckova M., Dolezal M., Staud F., Jampilek J., Kaustova J. Salicylanilide Acetates: Synthesis and Antibacterial Evaluation. Molecules. 2007;12:1–12. doi: 10.3390/12010001. PubMed DOI PMC

Imramovský A., Férriz J.M., Pauk K., Krátký M., Vinšová J. Synthetic route for the preparation of 2-hydroxy-N-[1-(2-hydroxyphenylamino)-1-oxoalkan-2-yl]benzamides. J. Comb. Chem. 2010;12:414–416. doi: 10.1021/cc900168s. PubMed DOI

Gwaltney S.L., Imade H.M., Li Q., Gehrke L., Credo R.B., Warner R.B., Lee J.Y., Kovar P., Frost D., Ng S.C., Sham H.L. Novel Sulfonate Derivatives: Potent Antimitotic Agents. Bioorg.Med. Chem. Lett. 2001;11:1671–1673. doi: 10.1016/S0960-894X(01)00279-7. PubMed DOI

Waisser K., Bureš O., Holý P., Kuneš J., Oswald R., Jirásková L., Pour M., Klimešová V., Kubicová L., Kaustová J. Relationship between the structure and antimycobacterial activity of substituted salicylanilides. Arch. Pharm. Pharm. Med. Chem. 2003;1:53–71. PubMed

Ferriz J.M., Vávrová K., Kunc F., Imramovský A., Stolaříková J., Vavříková E., Vinšová J. Salicylanilide carbamates: Antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains. Bioorg.Med. Chem. 2010;18:1054–1061. doi: 10.1016/j.bmc.2009.12.055. PubMed DOI

Kaustová J. Quantitative micromethod for drug susceptibility testing of mycobacteria in Šula´s medium. Klin.Microbiol. Inf. Lek. 1997;3:115–124.

The Structure-Antimicrobial Activity Relationships of a Promising Class of the Compounds Containing the N-Arylpiperazine Scaffold

Antibacterial activity of salicylanilide 4-(trifluoromethyl)-benzoates

Antimycobacterial assessment of Salicylanilide benzoates including multidrug-resistant tuberculosis strains